HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...
Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense ...
The firm will pay $45 million upfront for several new targeted agents that it plans to pair with isotopes to develop both ...
The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...
This marks the first US approval for AstraZeneca and Daiichi Sankyo's Trop-2-directed antibody drug conjugate.
Although Pfizer is not among the drugmakers suing the government to block negotiations, it has said the program will hinder drug R&D and innovation.
The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.
The firm aims to advance two breast cancer therapies in HR-positive, HER2-negative advanced breast cancer this year.
OIG Recommends Changes in FDA Accelerated Approval After Flagging Concerns With Aduhelm, Other Drugs
The OIG recommended that the FDA define factors that would trigger an application's review by an agency council, which the agency disagreed with.
NEW YORK – First Ascent Biomedical on Monday announced that it has received a $6 million investment from Vidal Duart Enterprises, as well as an additional co-investment from Techstars, which it will ...
The firm is aiming to break even on its cash flow by 2027 by narrowing its focus on its sarcoma treatments and pipeline candidates with the greatest potential.
The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback